Redeye remains positive on the investment case in Xbrane Biopharma following its Q3 2022 report.
Redeye concludes that Q3 was good but slightly below Redeye’s estimates.
Redeye states that the Q3 report was strong. Investment Management once again exceeded Redeye’s esti...
Redeye sees a Q3 report in line with preliminary figures, where North America and Sweden were substa...
Redeye provides a preview ahead of Embracer Group’s Q2 2022/23 report, due on 17th November.
Redeye comments on BioInvents report for the third quarter, which saw a further strengthening of the...
On 27 October 2022, Vow released its Q3 update (the company reports semi-annually), posting nearly d...
CapMan reported Q3 EBIT of EUR 12.7m, 7% above Refinitiv consensus.
Q3 sales grew 26% organically, +2% vs cons Guides for strong Q4 & H1 2023 from ATH order book Consen...
Solid Q3 but growth initiatives hurt margins We expect lower profitability mid-term ‘22e P/E of 7.
EPS and EBITDA 29% and 27% below ABGSCe Joinery and Pellets better than expected Strong cash flow re...
Redeye comments on Invisio’s Q3-results which showed strong growth and revenue slightly above our ex...
Monivent meddelade att bolaget har ingått en avsiktsförklaring tillsammans med American Academy of P...
AlphaHelix publicerade den 27 oktober 2022 bolagets delårsrapport för det tredje kvartalet 2022.
Q-linea and Thermo Fisher formed the collaboration in rearly February 2020.
Redeye will revise its estimates on the back of Bambuser’s Q3 report, which beat expectations on ARR...
Redeye briefly comments on Beyond Frames' new partnership with the Chinese VR hardware YVR regarding...
Lönsamhet når nya nivåer… Omsättningen i kvartalet uppgick till 32,7 mkr vilket motsvarar en tillväx...
Fortsatt stark och bred efterfrågan Med 16% organisk tillväxt var orderingången över 600 mkr för tre...
Mendus has drawn down its first loan of SEK10m as part of the company’s binding commitment with its ...
